Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

​

Efficacy, safety and tolerability of an orally administered cannabis extractin the treatment of spasticity in patients with multiple sclerosis: arandomized, double-blind, placebo-controlled, crossover study

​

Smoked cannabis for spasticity in multiple sclerosis:a randomized, placebo-controlled trial

​

Sativex for the management of multiple sclerosis symptoms

 

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis

 

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity

 

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors

 

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial

 

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis

 

Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis

 

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

 

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain

 

Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain